DALLAS, March 20, 2019 (GLOBE NEWSWIRE) -- via
OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (KALY) (“KALYâ€)
today announced the company plans to publish its phase one research
on the pilot treatment of Chronic Obstructive Pulmonary
Disease (COPD) in primates. The research paper comes
from Professor Jeffry Osbourn, Ph.D., from the University of
Kentucky and the principal of Biomedical Science Research Group
(BSRG). Professor Osbourn and KALY CEO Frederick Ferri met
last week to coordinate a phase two study of the pilot
treatment. The primate study adds to the Kali-Extracts in
vitro genomics study, previously announced, to evaluate the impact
of its pharmaceutical grade cannabis extracts in combination with
other therapies on COPD patients. The World Health
Organization estimates 65 million people worldwide are afflicted
with moderate to severe COPD and GlobalData forecasts that the COPD
treatment market will reach $14.1 billion by 2025.
KALY is a health and wellness company set to
generate revenue from its patented cannabis extraction technology
through overlapping go-to-market strategies. In addition to
developing pharmaceutical products internally and through
partnerships, KALY is utilizing is patented cannabis extraction
process to develop numerous wellness products both internally and
through partnerships. The company has made recent advances in
partnership with Puration, Inc. (PURA)
(“PURAâ€) developing a CBD extract for infusion into a beverage at a
25 mg concentration. The first target beverage for the 25 mg CBD
concentrate beverage is a private labeled health water for Generex
Biotechnology (GNBT).
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459